AF solution
Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Pancreatic Ductal Adenocarcinoma (PDAC) is a challenging disease due to its aggressive nature and complex biology, necessitating effective therapeutic strategies. Pre-clinical models using PDAC organoids combined with real-time monitoring are essential for assessing therapy response. Researchers developed stable live-imaging organoid/peripheral blood mononuclear cells (PBMCs) co-cultures and introduced OrganoIDNet, a deep-learning algorithm, to analyze bright-field images of murine and human PDAC organoids.
Â
The study assessed the response of PDAC organoids to the chemotherapy drug gemcitabine and the PD-L1 inhibitor Atezolizumab, with and without HLA-matched PBMCs over time. OrganoIDNet’s results were validated using the CellTiter-Glo proliferation assay. Live cell imaging with OrganoIDNet effectively detected size-specific drug responses, revealing that larger organoids were more susceptible to gemcitabine’s cytotoxic effects. This method also differentiated between healthy and unhealthy organoids and measured their eccentricity as a reaction to therapy.
Â
Additionally, the imaging of organoid/PBMCs sandwich-based co-cultures allowed for the longitudinal analysis of organoid responses to Atezolizumab, demonstrating increased PBMCs tumor-killing potency in the presence of the drug. This approach provides a platform for accurately detecting organoid responses to standard PDAC chemotherapy over time and offers dynamic insights into immunotherapeutic effects in individual patient-derived PDAC organoids, promising real-time assessment of immunotherapy effects.
Keywords: organoids, pancreatic cancer, AI
@ 2024 . All rights reserved
@ 2024 . All rights reserved
Log in to MyLab and
download your gift voucher from the ‘Vouchers’ menu!
Thank you for your continued trust and partnership.
We look forward to serving you with excellence.